SoftOx Solutions AS: Final result of the Subsequent Offering and allocation of Offer Shares

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES (OR ANY OTHER
JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE
UNLAWFUL). THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE
SECURITIES DESCRIBED HEREIN.

Reference is made to the stock exchange notices from SoftOx Solutions AS (the
"Company") regarding the subsequent offering of up to 125,000,000 new shares
(the "Subsequent Offering") at a subscription price of NOK 0,2 per share (the
"Offer Shares").

The subscription period for the Subsequent Offering expired on 29 April 2024 at
16:30 (CEST). The final number of valid subscriptions received in the Subsequent
Offering is 13.345.951. As a result, a total of 13.345.951 Offer Shares will be
allocated based in accordance with the allocation criteria set out in the
Prospectus. The gross proceeds from the Subsequent Offering is approximately NOK
2,7 million.

Notifications of allocated Offer Shares in the Subsequent Offering and the
corresponding amount to be paid by each subscriber will be sent out in a
separate letter to each valid subscriber today, 30 April 2024. 

Following registration of the Offer Shares pertaining to the Subsequent
Offering, the Company will have a share capital of NOK 10.335.392,82 divided
into 516,769,641 shares, each with a par value of NOK 0.02.

Sparebank 1 Markets is acting as manager in the Subsequent Offering. Kvale
Advokatfirma acts as legal advisor in the Subsequent Offering.

For any questions please contact: 
Geir Almås, Chair of SoftOx Solutions AS 
Mail: [e-mail] 
Phone: Geir Almås: ([phone] 
About SoftOx Solutions AS 

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange